41 completed, 24 active not recruiting, 14 terminated, 12 recruiting. 39 Phase 3, 16 Phase 4, 14 Phase 2, 7 Phase 1, 2 Not applicable.
Follow ocrelizumab: new trials by email Literature Review of ocrelizumab trials Research Report on ocrelizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) Ocrelizumab co-formulated with rHuPH20 - Relapsing-remitting Multiple Sclerosis | Phase 2 | Not yet recruiting | Hoffmann-La Roche | 25 | 2026-10-30 | 2026-10-14 |
| Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis Ocrelizumab - Relapsing-Remitting Multiple Sclerosis | Recruiting | Hoffmann-La Roche | 1800 | 2026-09-30 | 2026-09-28 | |
| Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis. Remibrutinib, Ocrelizumab (US) - Multiple Sclerosis (MS) - Relapsing-remitting | Recruiting | Washington University School of Medicine | 15 | 2026-08-15 | 2026-08-11 | |
| IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis IDP-023, Ocrelizumab, Interleukin-2 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS) | Phase 1 | Suspended | Indapta Therapeutics, INC. | 34 | 2026-06-30 | 2025-04-30 |
| A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab) - Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy | Phase 3 | Recruiting | University Hospital, Montpellier | 250 | 2026-06-15 | 2026-06-23 |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) RO7268489, Ocrelizumab, Placebo - Progressive Multiple Sclerosis | Phase 2 | Recruiting | Hoffmann-La Roche | 360 | 2026-03-10 | 2026-10-07 |
| Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis Ublituximab, Ocrelizumab - Multiple Sclerosis | Phase 4 | Recruiting | Johns Hopkins University | 50 | 2026-02-10 | 2026-05-06 |
| Immune System Effects in Children Born to Women With Multiple Sclerosis Treated With Monoclonal Antibody Therapy During Pregnancy monoclonal CD-20 antibodies, No Drug, Other treatment - Multiple Sclerosis, Pregnancy | Not yet recruiting | Region Stockholm | 111 | 2026-02-01 | 2025-11-25 | |
| People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists GLP-1, Ocrelizumab (US) - Multiple Sclerosis | Recruiting | Northwestern University | 100 | 2025-11-15 | 2026-03-17 | |
| A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis BCD-281, Ocrelizumab - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Recruiting | Biocad | 292 | 2025-11-01 | 2026-01-06 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis Ocrelizumab - Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 4 | Active not recruiting | Hoffmann-La Roche | 60 | 2025-07-04 | 2026-09-30 |
| Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. Remibrutinib oral treatment, Ocrelizumab - Relapsing Multiple Sclerosis | Phase 3 | Recruiting | Novartis Pharmaceuticals | 400 | 2025-06-23 | 2026-08-26 |
| Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis CYB704, Ocrevus-EU, Ocrevus-US - Relapsing Multiple Sclerosis | Phase 3 | Active not recruiting | Sandoz | 183 | 2025-06-10 | 2026-05-29 |
| B-cell Depletion in Offspring to Women With MS Under Immunomodulatory Treatment Anti-CD20 Monoclonal Antibody - Multiple Sclerosis, B-Cell Deficiency | Unknown | Region Stockholm | 111 | 2025-06-01 | 2024-12-02 | |
| A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations RPH-035, Ocrevus® - Multiple Sclerosis | Phase 1 | Active not recruiting | R-Pharm | 180 | 2025-04-16 | 2026-07-14 |
| Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis Ocrelizumab - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Enrolling by invitation | University of California, San Francisco | 5 | 2025-02-04 | 2026-03-27 |
| Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) Ocrelizumab (US), Ocrelizumab (EU), ABP 692 - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Active not recruiting | Amgen | 152 | 2025-01-13 | 2026-09-22 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis Ocrelizumab Co-formulated With rHuPH20 - Multiple Sclerosis | Phase 1 | Active not recruiting | Hoffmann-La Roche | 75 | 2024-12-17 | 2026-08-13 |
| An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment Ocrelizumab - Multiple Sclerosis | Phase 3 | Recruiting | Hoffmann-La Roche | 500 | 2024-12-13 | 2026-02-18 |
| A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS) Ocrelizumab - Multiple Sclerosis | Recruiting | Hoffmann-La Roche | 842 | 2024-09-26 | 2026-10-13 |
Showing 20 of 103. Sign in to see all of them.
Multiple Sclerosis (52) · Multiple Sclerosis, Relapsing-Remitting (27) · Multiple Sclerosis, Chronic Progressive (17) · Arthritis, Rheumatoid (8) · Recurrence (4) · Immune System Diseases (3) · Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Demyelinating Diseases (2) · Lupus Erythematosus, Systemic (2) · Nervous System Diseases (2) · Arthritis (1) · Body Weight (1) · Breast Feeding (1) · Demyelinating Autoimmune Diseases, CNS (1)
Hoffmann-La Roche (30) · Genentech, Inc. (13) · Johns Hopkins University (5) · Novartis Pharmaceuticals (5) · State University of New York at Buffalo (3) · University of California, San Francisco (3) · Haukeland University Hospital (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Region Stockholm (2) · Amgen (1) · Amsterdam UMC, location VUmc (1) · Assistance Publique - Hôpitaux de Paris (1) · Biocad (1) · Biogen (1) · Brigham and Women's Hospital (1)
United States (62) · France (27) · Spain (22) · Germany (21) · Italy (21) · Canada (20) · United Kingdom (20) · Poland (19) · Switzerland (18) · Belgium (17) · Brazil (16) · Russia (16) · Australia (15) · Mexico (15) · Bulgaria (13)
Wolfgang Dummer, M.D. (4) · Amit Bar-Or, M.D. (1) · Anne Kristine Lehmann, MD, PhD (1) · Astrid Kittang, MD, PhD (1) · Bardia Nourbakhsh (1) · Bardia Nourbakhsh, MD, MAS (1) · Bruce Cree, MD, PhD, MAS (1) · Bruno Stankoff, MD Ph.D (1) · Claudio Gobbi, MD (1) · Daniel Ontaneda, MD, MSc (1) · Einar Kristoffersen, MD, PhD (1) · Ellen M. Mowry, MD, MCR (1) · Enrique Alvarez, MD, PhD (1)
PMID 40258203, PMID 24498318, PMID 42328798, PMID 28002679, PMID 35672926, PMID 36163349, PMID 36792367, PMID 37652990, PMID 40629721, PMID 28002688, PMID 32511687, PMID 32690791, PMID 33724637, PMID 34904871, PMID 37148240, PMID 39290861, PMID 39812825, PMID 39965438, PMID 40554392, PMID 40970353, PMID 42208560, PMID 42832215, PMID 11405811, PMID 11911515, PMID 16678208, PMID 18759293, PMID 21261965, PMID 21905001, PMID 22047971, PMID 22247354, PMID 22389919, PMID 24631802, PMID 25125777, PMID 30155979, PMID 30415593, PMID 32503093, PMID 32727835, PMID 33129442, PMID 33724638, PMID 34555839, PMID 34748672, PMID 35129803, PMID 36007299, PMID 36031693, PMID 37008796, PMID 37094998, PMID 37356256, PMID 38071574, PMID 38649522, PMID 38654416
2023 (7), 2015 (3), 2017 (3), 2004 (2), 2016 (2), 2018 (2), 2025 (2), 2019 (1), U01AI195194 (1), UM1AI109565 (1)